CAIRE Diagnostics Inc.

CAIRE Diagnostics Inc. specializes in professional diagnostic spirometers. These devices measure lung function by assessing airflow and volume during breathing tests, helping clinicians evaluate respiratory conditions like asthma, COPD, and other pulmonary disorders. They are designed for use in clinical settings such as hospitals, doctor’s offices, and respiratory care facilities.

CAIRE Diagnostics Inc. is headquartered in the United States. The company’s location influences its regulatory compliance, particularly for devices marketed in the US and EU, where spirometers are subject to distinct classification and registration requirements.

CAIRE Diagnostics Inc.’s devices are listed in the EU’s EUDAMED database and the US FDA Unique Device Identifier (UDI) system. These registries ensure transparency in device tracking and compliance with regional regulatory frameworks, such as the EU’s MDR and the US FDA’s premarket requirements.

CAIRE Diagnostics Inc.’s spirometers fall under EU Class A and US Class I/II classifications, depending on the specific model and intended use. Class A (EU) and Class I (US) generally apply to low-risk devices like diagnostic spirometers, while Class II (US) may apply if additional safety features or performance criteria are involved. Classification determines regulatory pathways, such as conformity assessment procedures or post-market surveillance requirements.